NCT06904040View on ClinicalTrials.gov

A Single-center Study of CM313 in Patients With Pemphigus

NANot yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

April 1, 2028

Conditions
Pemphigus
Interventions
BIOLOGICAL

CM313 injection

600 mg (4 mL per vial), administer once at Week 0, 1, and 2, and then every 6 months thereafter or determined based on clinical assessment

BIOLOGICAL

glucocorticoids

Administer medium- or long-acting glucocorticoids 1-3 hours before injection

Trial Locations (1)

Unknown

Sichuan Provincial People's Hospital, Chengdu

All Listed Sponsors
lead

Sichuan Provincial People's Hospital

OTHER

NCT06904040 - A Single-center Study of CM313 in Patients With Pemphigus | Biotech Hunter | Biotech Hunter